Goldman Sachs keeps a Neutral rating and $340 price target on HCA Healthcare after its Q2 earnigns beat and guidance raise. The company’s Q2 performance highlights a continued strong utilization environment, strong payor mix and acuity, and effective cost containment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Announces Strong Q2 Performance and Dividend
- HCA Earnings this Week: How Will it Perform?
- HCA Healthcare price target raised to $362 from $317 at Bernstein
- HCA Healthcare price target raised to $376 from $367 at Barclays
- HCA Healthcare price target raised to $375 from $359 at Deutsche Bank